Descriptive analysis of the Nationwide START2 antiphospholipid registry: Clinical and laboratory characteristics of patients with persistently positive antiphospholipid antibodies.

Women were overrepresented among carriers (76% vs 62%, p = 0.002).

Laboratory profiles were similarly distributed across Antiphospholipis Syndrome and carriers: triple positivity (43% vs 44%), double positivity (13% vs 12%), and isolated LA positivity (23% vs 30%).

After a first venous thromboembolism, most Antiphospholipis Syndrome patients received warfarin (62%), whereas arterial Antiphospholipis Syndrome was treated with either warfarin (51%) or aspirin (37%).

Among carriers, aspirin was the preferred prophylactic strategy (45%).